Molbio Diagnosti Q1 FY27 Share Price & Earnings Call Analysis

Management guidance · Q1 FY27 call

Molbio Diagnosti ranks #1 of 5 in Healthcare Equipment & Supplies on what management guided

Revenue growth 20–40%Margin flat

Leading Healthcare Equipment & Supplies companies on guidance

  1. 1.Fischer Medical Ventures LtdRevenue growth 10–20%
  2. 2.Revenue growth 10–20%
Full Healthcare Equipment & Supplies ranking →Check your portfolio against these rankings →All companies ranked →

Sign up free to see every company in the sector ranking and track Molbio Diagnosti.

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Financials of Molbio Diagnosti

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Molbio Diagnosti

Shareholding breakup across reporting periods.

Aug 2026
Promoters +41.29%
FIIs +1.51%
DIIs +16.36%
Government +0.02%
Public +40.83%
No. of Shareholders2,33,544

Financials of Molbio Diagnosti

Quarterly Results

Quarter-by-quarter operating performance

Jun 2025Mar 2026Jun 2026
Sales +95439399
Expenses +105332308
Operating Profit-1010792
OPM %-10%24%23%
Other Income +131
Interest299
Depreciation7108
Profit before tax-179176
Tax %-23%28%25%
Net Profit +-136657
EPS in Rs-5.955.835.02

Financials of Molbio Diagnosti

Profit & Loss

Annual income statement trend

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +1,2717763277569711,313
Expenses +6764572865527461,061
Operating Profit59531940204226252
OPM %47%41%12%27%23%19%
Other Income +158-21-24
Interest352568923
Depreciation124219242636
Profit before tax54925823152188198
Tax %25%27%32%27%26%27%
Net Profit +41018716111140145
EPS in Rs2,027.06833.3769.00493.0162.0012.83
Dividend Payout %0%0%0%0%0%0%

Financials of Molbio Diagnosti

Balance Sheet

Capital structure and asset base

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital2222211
Reserves3336817378489881,123
Borrowings +257105577026346
Other Liabilities +21585123157291260
Total Liabilities8068749201,0771,3071,741
Fixed Assets +55182189209215257
CWIP100002186
Investments99545495317
Other Assets +6436836768139801,160
Total Assets8068749201,0771,3071,741

Financials of Molbio Diagnosti

Cash Flows

Operating, investing and financing cash movement

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +344986838249-38
Cash from Investing Activity +-142-87-51-31-98-256
Cash from Financing Activity +-192-2031-24-17292
Net Cash Flow10-948-18133-2
Free Cash Flow212355524206-74
CFO/OP78%53%251%39%139%6%

Financials of Molbio Diagnosti

Ratios

Working capital efficiency and return ratios

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6111319417486100
Inventory Days261402885393395286
Days Payable12464201129226130
Cash Conversion Cycle198450877438254256
Working Capital Days75206479239155143
ROCE %41%4%22%21%18%

Continue your research

What Molbio Diagnosti's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • QMS Medical Allied Services Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how

  • Avience Biomedicals Ltd (Q1 FY27)

    New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…

  • Fischer Medical Ventures Ltd (Q2 FY25)

    EBITDA: ₹36.3 crore, a 45.5% year-on-year increase. Key concall takeaways from Fischer Medical Ventures Ltd's Q2 FY25 earnings call — and how it ranks against…

  • Fischer Medical Ventures Ltd (Q1 FY27)

    The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…

Compare:vs Fischer Medical Ventures Ltdvs Tarsons Products Ltdvs Q-Line Biotech Ltd